2024-03-29T07:51:55Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1347422018-09-07T07:19:15Zcom_10261_112com_10261_1com_10261_11773col_10261_365col_10261_11774
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma
Paiva, Bruno
Vidriales, Maria Belén
Colado, Enrique
Caballero-Velázquez, Teresa
García de Coca, Alfonso
García-Sanz, Ramón
Ocio, Enrique M.
Mateos, Maria Victoria
San Miguel, Jesús F.
Instituto de Salud Carlos III
Junta de Castilla y León
Asociación Española Contra el Cáncer
Red Temática de Investigación Cooperativa en Cáncer (España)
Solitary plasmacytoma represents a heterogeneous group of patients; approximately half develop multiple myeloma (MM) in 2 or 3 years,whereas others remain disease-free at 10 years. By definition, these patients do not have morphologic bone marrow (BM) plasma cell (PC) infiltration. Here, we investigated whether sensitive BM evaluation of patients withsolitaryboneplasmacytoma(SBP; n = 35) andextramedullary plasmacytoma (EMP; n = 29) through multiparameter flow cytometry (MFC) would unravel the presence of clonal PCs in otherwise disease-free BM, and whether BMclonality predicted higher risk of progression. BMclonal PCs were detected in 17 of 35 SBP (49%) and 11 of 29 EMP (38%) patients. Seventy-one percent of flow-positive vs only 8% of flow-negative SBP patients evolved to MM (median time to progression of 26 months vs not reached; hazard ratio, 17.4; P < .001). No significant differences were observed among EMP cases. Our results highlight the importance of MFC for sensitive BM evaluation of SBP patients, to predict risk of developing treatment-requiring MM and to plan disease monitoring.
2016-07-13T10:49:20Z
2016-07-13T10:49:20Z
2014
2016-07-13T10:49:20Z
artículo
Blood 124(8): 1300-1303 (2014)
http://hdl.handle.net/10261/134742
10.1182/blood-2014-04-567909
http://dx.doi.org/10.13039/501100004587
http://dx.doi.org/10.13039/501100014180
eng
Sí
closedAccess
American Society of Hematology